Business
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation\nCHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 \n\n \n \n \n \n \n \n\n \n\"Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand,\" said Charles \"Chuck\" Henderson, the ADA's chief executive officer. \"Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready.\"\nIt is estimated that up to 46% of people with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event each year.2 Hypoglycemia is conservatively responsible for more than 202,000 emergency department visits annually with approximately 25% being admitted to the hospital.3 This is unacceptable. More needs to be done to protect people at risk for severe hypoglycemia.\nThe ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net.\n\"Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate wit...